![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Inc. Signs R&D Collaboration Letter of Intent Agreement With Aeras Global TB Vaccine Foundation
February 01, 2010 14:13 ET
|
TapImmune Inc.
BELLEVUE, Wash., Feb. 1, 2010 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced that it has signed a Letter of Intent (LOI) with Aeras Global TB Vaccine Foundation to enter into an R&D...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune, Inc. Retains Wolfe Axelrod Weinberger Associates LLC as Its Investor Relations Counsel
January 12, 2010 10:00 ET
|
TapImmune Inc.
BELLEVUE, Wash., Jan. 12, 2010 (GLOBE NEWSWIRE) -- TapImmune, Inc. (OTCBB:TPIV) announced that it has retained Wolfe Axelrod Weinberger Associates LLC as its investor relations counsel to communicate...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune, Inc. to Present at OneMedPlace Forum 2010
January 11, 2010 10:00 ET
|
TapImmune Inc.
BELLEVUE, Wash., Jan. 11, 2010 (GLOBE NEWSWIRE) -- TapImmune, Inc. (OTCBB:TPIV) announced today President Denis Corin will be presenting at the OneMedPlace's Forum 2010, Emerging Company Finance...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Announces Additional Funding
November 25, 2009 14:00 ET
|
TapImmune Inc.
BELLEVUE, Wash., Nov. 25, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Signs License Agreement With Crucell N.V.
November 05, 2009 09:00 ET
|
TapImmune Inc.
BELLEVUE, Wash., Nov. 5, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases,...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Signs License Agreement With Crucell N.V.
November 04, 2009 09:00 ET
|
TapImmune Inc.
BELLEVUE, Wash., Nov. 4, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Receives BUY Recommendation From the KonLin
October 07, 2009 09:30 ET
|
TapImmune Inc.
BELLEVUE, Wash., Oct. 7, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases,...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Provides Shareholder Update
October 01, 2009 09:30 ET
|
TapImmune Inc.
BELLEVUE, Wash., Oct. 1, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases,...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Inc. Announces Agreement With AppTec
August 16, 2007 10:56 ET
|
TapImmune Inc.
VANCOUVER, British Columbia, Aug. 16, 2007 (PRIME NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIM) (Germany:GX1A), a biotechnology company specializing in the development of immunotherapeutics for cancer and...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Provides Operational Update Including Human Data Supporting Use of TAP-Based Cancer Vaccine
August 01, 2007 11:03 ET
|
TapImmune Inc.
VANCOUVER, British Columbia, Aug. 1, 2007 (PRIME NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for...